Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease – Cancer Network
Cancer Network |
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease
Cancer Network In August 2017, Drs. Kurzrock and Kato and colleagues published a study[1] analyzing potential genetic biomarkers of so-called “hyperprogressors”—cancer patients who had been treated with an anti–programmed death 1 (PD-1) or anti–programmed death … |
